Nalaganje...
Off-Label Use of Rituximab in a Multipayer Insurance System
PURPOSE: Off-label prescribing in oncology is common and unregulated. The aim of this study was to describe the off-label use of rituximab, a novel anti-CD20 antibody, among patients from a large proprietary insurance database to understand how frequently and appropriately off-label prescribing occu...
Shranjeno v:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Clinical Oncology
2011
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3051865/ https://ncbi.nlm.nih.gov/pubmed/21731512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.2010.000042 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|